The results showed that the expressions of inhibitory immune checkpoint, such as PD-1, CTLA-4, LAG3, TIM3 and TIGIT, in C2 were increased compared to those in C1, which hinted that HCC patients in C1 might be better responsive to immunotherapy. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.